Healthcare Industry News: immune modulator
News Release - August 4, 2008
Pluristem Appoints Ms. Chaya Mazouz Clinical Operations DirectorNEW YORK--(HSMN NewsFeed)--Pluristem Therapeutics Inc. (NasdaqCM:PSTI); (DAX:PJT), a bio-therapeutics company dedicated to the commercialization of non-personalized (allogeneic) cell therapy products for a variety of degenerative, ischemic and autoimmune indications, announced today that Ms. Chaya Mazouz was appointed the Companyís Clinical Operations Director.
Ms. Chaya Mazouz has extensive experience in planning and managing clinical and regulatory activities (Phase I to Phase III) for drugs, devices and cell products. Ms. Mazouz previously held the position of Clinical Operations Director for a clinical-stage biopharmaceutical company (Medgenics) involving gene therapy, where she engineered Phase I/II clinical studies. Prior to that, she served as Clinical Manager for a drug delivery company (TransPharma Medical) where she was responsible for managing all of the companyís clinical activities. In previous positions, Ms. Mazouz led a multi-center Phase II study for a pharmaceutical company (Pharmos Ltd.), and was CRA and Project Manager at a startup company engaged in gene discovery (IDgene).
Zami Aberman, Pluristemís President and CEO said: "We are proud that Ms. Mazouz has joined our experienced team and believe she will be highly successful in leading the support and planning process for all our future human clinical studies."
Pluristem Therapeutics Inc. is a bio-therapeutics company dedicated to the commercialization of non-personalized (allogeneic) cell therapy products for the treatment of several severe degenerative, ischemic and autoimmune disorders. The Company is developing a pipeline of products, stored ready-to-use, that are derived from human placenta, a non-controversial, non-embryonic, adult stem cell source.
These placental mesenchymal stromal cells (MSCs) are expanded in the Company's proprietary PluriXTM 3D bioreactor, which imitates the natural microstructure of bone marrow and does not require supplemental growth factors or other exogenous materials. Pluristem believes that the resultant PLX (PLacental eXpanded) cells are multi-potent and able to differentiate into a variety of cell types. Recent evidence also suggests their efficacy may be related to the secretion of cytokines or other potent immune modulators. Furthermore, PLX cells are immune privileged and have immunomodulatory properties, thus protecting the recipient from immunological reactions that often accompany transplantations.
Pluristem's first product in development, PLX-PAD, is intended to improve the quality of life of millions of people suffering from peripheral artery disease (PAD). The Company's products in development also include PLX-BMT, targeting the global shortfall of matched tissue for bone marrow transplantation (BMT) by improving the engraftment of hematopoietic stem cells (HSCs) contained in umbilical cord blood; PLX-STROKE, targeting ischemic stroke; PLX-MS, targeting Multiple Sclerosis; and PLX-IBD, targeting Inflammatory Bowel Disease (IBD), which includes Crohnís disease and Ulcerative Colitis.
Pluristem has offices in the USA with research and manufacturing facilities in Israel.
See our product animation on YouTube: http://www.youtube.com/watch?v=OFhWXyJT6Us
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and federal securities laws. These forward-looking statements are based on the current expectations of the management of Pluristem only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. For example, when we say that we believe Ms. Mazouz will be highly successful in leading the support and planning process for all our future human clinical studies, we are using a forward-looking statement. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; our technology may not be validated as we progress further and our methods may not be accepted by the scientific community; we may be unable to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties may develop with our process; results in the laboratory may not translate to equally good results in real surgical settings; our patents may not be sufficient ;our products may harm recipients; changes in legislation; inability to timely develop and introduce new technologies, products and applications; loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of Pluristem to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Pluristem undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risk and uncertainties affecting Pluristem, reference is made to Pluristem's reports filed from time to time with the Securities and Exchange Commission.
For more information visit our website at www.pluristem.com, the content of which is not part of this press release.
Source: Pluristem Therapeutics
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.